Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY23 results · Jul–Sep 2022
Astec LifeSciences reported revenue from operations of ₹199.75 crore (up 94.7% from Q2 FY22) and net profit of ₹18.31 crore (up 101.8% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 199.75 | 102.57 | +94.7% | 184.27 | +8.4% |
| Other income | 3.99 | 0.90 | +343.2% | 2.71 | +47.1% |
| Total income | 203.73 | 103.47 | +96.9% | 186.98 | +9.0% |
| Profit before tax | 24.58 | 12.18 | +101.8% | 15.31 | +60.6% |
| Net profit for the period | 18.31 | 9.08 | +101.8% | 11.41 | +60.6% |
| Attributable to shareholders of the company | 18.31 | — | — | 11.40 | +60.6% |
| EPS, basic (₹) | 9.34 | 4.63 | +101.6% | 5.82 | +60.6% |
| Net margin (%) | 9.2 | 8.8 | 6.2 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 199.75 | 102.57 | +94.7% | 184.27 | +8.4% |
| Other income | 3.98 | 0.90 | +342.8% | 2.71 | +47.1% |
| Total income | 203.73 | 103.47 | +96.9% | 186.97 | +9.0% |
| Profit before tax | 24.56 | 12.16 | +102.0% | 15.29 | +60.7% |
| Net profit for the period | 18.30 | 9.06 | +101.9% | 11.39 | +60.7% |
| EPS, basic (₹) | 9.34 | 4.63 | +101.9% | 5.81 | +60.8% |
| Net margin (%) | 9.2 | 8.8 | 6.2 |
Consolidated
- Filed with BSE
- 29 Oct 2022, 11:59 IST
- Board meeting
- 28 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2022, 11:59 IST
- Board meeting
- 28 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE